A post-surgical infection, also known as a surgical site infection (SSI), refers to infections after a surgical procedure. Such infections can result in poor wound healing and pain and might require further treatment. A post-surgical infection often occurs within 30 days after a surgical procedure. Studies show that the chances of developing such an infection post-surgery are around 1 to 3%. The growth in the volume of surgical procedures, especially among older adults, coupled with the rising focus on infection control protocols is anticipated to aid in the drug pipeline expansion.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post-surgical infection.
Novel antibiotics and alternative therapies, such as antimicrobial peptides and bacteriophage treatments are increasingly being explored to combat resistant pathogens that cause post-surgical infections. Moreover, the rise in multidrug-resistant cases is shifting the focus towards phage therapy and CRISPR-modified bacteriophages to effectively target these bacterial strains.
Sponsored by MinaPharm Pharmaceuticals, the objective of the clinical trial is to evaluate the efficacy and safety of oral Ciprodiazole® in comparison to ciprofloxacin tablets and metronidazole tablets in pelvi-abdominal infections and after IV antibiotics in post-operative duration. The study is under Phase IV clinical development and has an estimated 312 participants.
This product will be delivered within 3-5 business days.
Report Coverage
The Post-Surgical Infection Drug Pipeline Insight Report by the publisher gives comprehensive insights into post-surgical infection drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for post-surgical infection. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The post-surgical infection pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from post-surgical infection.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post-surgical infection.
Post-Surgical Infection Drug Pipeline Outlook
A post-surgical infection can cause fever, tenderness, redness, delayed healing, or swelling, among others. There are three types of post-surgical infections: superficial incisional SSI, deep incisional SSI, and organ or space SSI. These infections are commonly caused by the bacteria Streptococcus, Staphylococcus, and Pseudomonas . Age, diabetes, obesity, and smoking are some of the risk factors for developing a post-surgical infection.Novel antibiotics and alternative therapies, such as antimicrobial peptides and bacteriophage treatments are increasingly being explored to combat resistant pathogens that cause post-surgical infections. Moreover, the rise in multidrug-resistant cases is shifting the focus towards phage therapy and CRISPR-modified bacteriophages to effectively target these bacterial strains.
Post-Surgical Infection - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of post-surgical infection drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Peptides
- Polymers
- Biologics
By Route of Administration
- Oral
- Parenteral
- Others
Post-Surgical Infection - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for post-surgical infection.Post-Surgical Infection - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the post-surgical infection pipeline analysis include small molecules, peptides, polymers, and biologics. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post-surgical infection.Post-Surgical Infection Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the post-surgical infection drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in post-surgical infection clinical trials:- MinaPharm Pharmaceuticals
- Aesculap AG
- PolyPid Ltd.
- Oticara Australia PTY LTD
- GeneOne Life Science, Inc.
Post-Surgical Infection - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Drug: Oral Ciprodiazole®Sponsored by MinaPharm Pharmaceuticals, the objective of the clinical trial is to evaluate the efficacy and safety of oral Ciprodiazole® in comparison to ciprofloxacin tablets and metronidazole tablets in pelvi-abdominal infections and after IV antibiotics in post-operative duration. The study is under Phase IV clinical development and has an estimated 312 participants.
Drug: povidone-iodine topical ointment
This Phase IV clinical study is aimed at evaluating intranasal povidone iodine (PVI) to prevent Staphylococcus aureus surgical site infections following orthopedic fixation procedures for high-energy lower extremity fractures. The interventional study has enrolled about 2000 subjects and is expected to be completed by February 2026.Reasons To Buy This Report
The Post-Surgical Infection Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for post-surgical infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within post-surgical infection pipeline insights.Key Questions Answered in the Post-Surgical Infection - Pipeline Insight Report
- What is the current landscape of post-surgical infection pipeline drugs?
- How many companies are developing post-surgical infection drugs?
- How many phase III and phase IV drugs are currently present in post-surgical infection pipeline drugs?
- Which companies/institutions are leading the post-surgical infection drug development?
- What is the efficacy and safety profile of post-surgical infection pipeline drugs?
- What are the opportunities and challenges present in the post-surgical infection drug pipeline landscape?
- Which company is conducting major trials for post-surgical infection drugs?
- What geographies are covered for post-surgical infection clinical trials?
- What are emerging trends in post-surgical infection clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Post-Surgical Infection
4 Patient Profile: Post-Surgical Infection
5 Post-Surgical Infection: Epidemiology Snapshot
6 Post-Surgical Infection: Market Dynamics
7 Post-Surgical Infection: Key Facts Covered
8 Post-Surgical Infection, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Post-Surgical Infection Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Post-Surgical Infection Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Post-Surgical Infection Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Post-Surgical Infection Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Post-Surgical Infection, Key Drug Pipeline Companies
